Tusamitamab Ravtansine provides a CEACAM5-targeting antibody-drug conjugate (ADC) for cancer and oncology research. Also known as SAR408701, it combines a CEACAM5-directed monoclonal antibody with the maytansinoid cytotoxic payload DM4 (ravtansine) and specifically supports studies of targeted cytotoxicity, non-small cell lung cancer, and antibody-mediated drug delivery.
Key Features and Benefits
- CEACAM5-Targeting ADC: Combines a CEACAM5-directed monoclonal antibody with the cytotoxic DM4 payload for targeted cancer research.
- DM4 Payload: Contains ravtansine, a potent maytansinoid microtubule inhibitor specifically studied in ADC development.
- CEACAM5 Recognition: Supports investigation of CEACAM5 expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Disulfide Linker: Uses a disulfide-containing linker that specifically enables intracellular processing and release of active DM4-derived metabolites.
- Targeted Payload Delivery: Supports investigation of antibody-mediated delivery of maytansinoid payloads to CEACAM5-expressing cancer cells.
- Microtubule Disruption: DM4 inhibits microtubule dynamics, specifically supporting studies of cell-cycle arrest and ADC-mediated cytotoxicity.
- Bystander Cytotoxicity: Supports investigation of cytotoxic effects associated with membrane-permeable DM4-derived metabolites in heterogeneous tumor models.
- SAR408701 Research Platform: Provides an investigational ADC platform specifically for studying CEACAM5-directed targeting and maytansinoid payload activity.
Applications
- Non-Small Cell Lung Cancer Research: Supports investigation of CEACAM5-targeted ADC mechanisms in NSCLC models.
- Lung Adenocarcinoma Research: Useful for studying CEACAM5 expression and ADC-mediated cytotoxicity in lung adenocarcinoma models.
- CEACAM5-Positive Cancer Research: Supports investigation of antibody targeting and cytotoxic responses in CEACAM5-expressing tumors.
- Colorectal Cancer Research: Useful for evaluating CEACAM5-directed ADC activity in relevant colorectal cancer models.
- ADC Research: Supports studies of antibody binding, internalization, intracellular processing, and payload release.
- Targeted Cancer Research: Enables investigation of antibody-mediated DM4 delivery to CEACAM5-expressing cancer cells.
- Cell-Based Cancer Assays: Useful for evaluating CEACAM5-dependent binding, cellular uptake, cytotoxicity, and apoptosis.
- Mechanism-of-Action Studies: Supports investigation of CEACAM5 targeting and DM4-mediated microtubule disruption.
- Comparative ADC Research: Useful for comparing antibody targets, disulfide linker systems, maytansinoid payloads, and ADC activity.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve antibody and conjugate stability.
Tusamitamab Ravtansine combines CEACAM5-directed antibody targeting with the microtubule-disrupting DM4 payload and specifically supports non-small cell lung cancer, CEACAM5-positive tumor, ADC, and targeted drug delivery research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
